

AMENDMENTS TO THE CLAIMS**In the Claims:**

Please amend claims 3-7, 9, 10, 12-17 in the following manner. This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Original) A tripeptide or tetrapeptide or an alkyl ester thereof comprising a proteolytic enzyme cleavable amino acid moiety as a drug or pharmacologically active site or pharmacologically active group transport and delivery system.
2. (Original) The tripeptide or tetrapeptide of claim 1, which is an alkyl ester with the alkyl group being a methyl or an ethyl group, preferably an ethyl group.
3. (Currently Amended) The tripeptide or tetrapeptide of claim 1 ~~or 2~~, wherein the proteolytic enzyme cleavable amino acid moiety is a not terminal moiety.
4. (Currently Amended) The tripeptide or tetrapeptide of claim 1 ~~anyone of the preceding claims~~ comprising a not terminal optionally substituted phenylalanyl moiety.
5. (Currently Amended) The tripeptide or tetrapeptide of claim 1 ~~anyone of the preceding claims~~ anyone of the preceding claims that is selected from the group consisting of substituted or unsubstituted Phe-Phe-Pro, Pro-Phe-Phe, Phe-Phe-Ser, Ser-Phe-Phe, Phe-Phe-Asn, Asn-Phe-Phe, Phe-Gly-Phe-Val (Seq. Id. No. 1), Val-Phe-Gly-Phe (Seq. Id. No. 2), Phe-Arg-Phe-His (Seq. Id. No. 3), His-Phe-Arg-Phe (Seq. Id. No. 4), Phe-Arg-Val, and Val-Arg-Phe[[,]] ~~whereby Pro-Phe-Phe is preferred.~~

6. (Currently Amended) The tripeptide or tetrapeptide of claim 1 ~~anyone of the preceding claims~~, wherein the terminal Phe is fluoro substituted in para position, in particular the peptide Pro-Phe-p-F-Phe.

7. (Currently Amended) ~~A~~ The tripeptide or tetrapeptide of claim 1 wherein the proteolytic enzyme cleavable amino acid moiety is substituted with a substituent sufficiently reactive to be useful in drug coupling reactions, with the proviso that said substituent is not – $N(CH_2-CH_2-Cl)_2$ in meta position on the not terminal Phe of Pro-Phe-p-F-Phe.

8. (Original) The tripeptide or tetrapeptide of claim 7 wherein the proteolytic enzyme cleavable amino acid moiety is or comprises Phe.

9. (Currently Amended) Use of a tripeptide or tetrapeptide as defined in claim 1 ~~anyone of the preceding claims~~ as substituent or part of a substituent of a drug[[,]] ~~in particular a drug for the treatment of, arthritis, invasive parasitic diseases, Paludism (Malaria), AIDS, and tumours, especially cancer.~~

10. (Currently Amended) A tripeptide or a tetrapeptide as defined in claim 1 ~~anyone of claims 1 to 8~~ that is connected to a drug or a pharmacologically active site or a pharmacologically active group, with the proviso that it is not prolyl-m-sarcolysyl-p-fluoro-phenylalanine.

11. (Original) The tripeptide or tetrapeptide of claim 10 wherein the drug is adriamycin.

12. (Currently Amended) Use A method of treating cancer comprising the administration of the tripeptide or tetrapeptide of claim 10 or 11 for the preparation of a medicament for the treatment of cancer.

13. (Currently Amended) Use A method of treating a condition selected from the group consisting of arthritis, non cancerous tumors, invasive parasitic diseases, Paludism (Malaria), and AIDS comprising the administration of a tripeptide or tetrapeptide as defined in claim 1 in anyone of claims 1 to 8 that is connected to a drug or a pharmacologically active site or a pharmacologically active group ~~for the preparation of a medicament for the treatment of arthritis, non cancerous tumours, invasive parasitic diseases, Paludism (Malaria), and AIDS.~~

14. (Currently Amended) A method for improving the efficiency of a drug and/or for reducing the side effects of a drug wherein said drug is coupled to or included in a transport system of claim 1 ~~one of claims 1 to 8.~~

15. (Currently Amended) Use of a drug of claim 10 ~~or 11~~ for the preparation of a medicament.

16. (Currently Amended) A pharmaceutical composition comprising a tripeptide or a tetrapeptide of claim 10 ~~or 11.~~

17. (Currently Amended) Method for the production of an active ingredient of a medicament comprising a transport and delivery system, wherein a drug or a pharmacologically active site or a pharmacologically active group is coupled with amino acids such that a tripeptide or a tetrapeptide as defined in claim 1 ~~one of claims 1 to 7~~ connected to a drug or a pharmacologically active site or a pharmacologically active group is generated, with the proviso that the pharmacologically active group is not $-N(CH_2-CH_2-Cl)_2$.

Please add new claims 18-19 as follows.

18. (New) The tripeptide or tetrapeptide of claim 1 that is a substituted or unsubstituted Pro-Phe-Phe.

19. (New) Use of a tripeptide or tetrapeptide as defined in claim 1 as a substituent or part of a substituent of a drug for treatment of a disease selected from the group consist of arthritis, non-cancerous tumors, invasive parasitic diseases, Paludism (Malaria), and AIDS.